Three-year analysis of the Belgian multidisciplinary immunotoxicity (BITOX) board: organization, feasibility, and results

Medicine and Dentistry

• Immunotoxicity 100%
• Immune-Related Adverse Events 100%
• Immune Checkpoint Inhibitor 75%
• Oncologist 50%
• Comorbidity 50%
• Immunosuppressive Treatment 25%
• Autoimmunity 25%
• Health Care Personnel 25%
• Medical Decision Making 25%
• Antibiotic Therapy 25%
• Autoimmune Disease 25%
• Oncology 25%
• Corticosteroid Therapy 25%
• Monotherapy 25%
• Organ Systems 25%
• Antiviral Therapy 25%
• Paraneoplastic Syndrome 25%
• Programmed Death 1 Receptor 25%
• Solid Organ Transplantation 25%

Nursing and Health Professions

• Adverse Event 100%
• Immunotoxicity 100%
• Comorbidity 50%
• Oncologist 50%
• Syndrome 25%
• Health Care Personnel 25%
• Medical Decision Making 25%
• Monotherapy 25%
• Organ Transplantation 25%
• Corticosteroid Therapy 25%
• Antibiotic Therapy 25%
• Immunosuppressive Treatment 25%
• Autoimmune Disease 25%
• Accident Prevention 25%
• Programmed Death 1 Receptor 25%
• Paraneoplastic Syndrome 25%
• Antiviral Therapy 25%